What happened
AprilBio reported separate results for FY2025: revenue of US$1.49M (−92.11% year on year), an operating loss of US$4.97M (from a profit a year earlier) and a net loss of US$6.65M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$1.49M |
|---|---|
| Revenue vs a year earlier | −92.11% |
| Operating profit | −US$4.97M |
| Net income | −US$6.65M |
| Period | FY2025 (separate) |
| Filed | 2026-02-09, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260209900780 → open original filing |
Source: DART. Information only, not investment advice.